277 related articles for article (PubMed ID: 20870723)
21. Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A.
Aguilera JJ; Zhang F; Beaudet JM; Linhardt RJ; Colón W
Biochimie; 2014 Sep; 104():70-80. PubMed ID: 24878279
[TBL] [Abstract][Full Text] [Related]
22. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
23. Altered dimer interface decreases stability in an amyloidogenic protein.
Baden EM; Owen BA; Peterson FC; Volkman BF; Ramirez-Alvarado M; Thompson JR
J Biol Chem; 2008 Jun; 283(23):15853-60. PubMed ID: 18400753
[TBL] [Abstract][Full Text] [Related]
24. Interaction between glycosaminoglycans and immunoglobulin light chains.
Jiang X; Myatt E; Lykos P; Stevens FJ
Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
[TBL] [Abstract][Full Text] [Related]
25. A glycosylated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues.
Foss GS; Nilsen R; Cornwell GC; Husby G; Sletten K
Scand J Immunol; 1998 Apr; 47(4):348-54. PubMed ID: 9600316
[TBL] [Abstract][Full Text] [Related]
26. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
27. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
28. Light chain amyloidosis - current findings and future prospects.
Baden EM; Sikkink LA; Ramirez-Alvarado M
Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145
[TBL] [Abstract][Full Text] [Related]
29. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
[TBL] [Abstract][Full Text] [Related]
30. Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen.
Ohishi H; Skinner M; Sato-Araki N; Okuyama T; Gejyo F; Kimura A; Cohen AS; Schmid K
Clin Chem; 1990 Jan; 36(1):88-91. PubMed ID: 2297939
[TBL] [Abstract][Full Text] [Related]
31. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
32. Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance.
Quittot N; Sebastiao M; Bourgault S
Biochem Cell Biol; 2017 Jun; 95(3):329-337. PubMed ID: 28177755
[TBL] [Abstract][Full Text] [Related]
33. Macromolecular properties of glycosaminoglycans in primary AL amyloid fibril extracts of lymphoid tissue origin.
Stenstad T; Magnus JH; Kolset SO; Cornwell GG; Husby G
Scand J Immunol; 1991 Nov; 34(5):611-7. PubMed ID: 1947796
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin light chains, glycosaminoglycans, and amyloid.
Stevens FJ; Kisilevsky R
Cell Mol Life Sci; 2000 Mar; 57(3):441-9. PubMed ID: 10823245
[TBL] [Abstract][Full Text] [Related]
35. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
[TBL] [Abstract][Full Text] [Related]
36. Kinetic analysis of the polymerization and depolymerization of beta(2)-microglobulin-related amyloid fibrils in vitro.
Yamamoto S; Hasegawa K; Yamaguchi I; Goto Y; Gejyo F; Naiki H
Biochim Biophys Acta; 2005 Nov; 1753(1):34-43. PubMed ID: 16084781
[TBL] [Abstract][Full Text] [Related]
37. Modulation of Abeta42 fibrillogenesis by glycosaminoglycan structure.
Valle-Delgado JJ; Alfonso-Prieto M; de Groot NS; Ventura S; Samitier J; Rovira C; Fernàndez-Busquets X
FASEB J; 2010 Nov; 24(11):4250-61. PubMed ID: 20585030
[TBL] [Abstract][Full Text] [Related]
38. Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
Iwahashi N; Ikezaki M; Nishikawa T; Namba N; Ohgita T; Saito H; Ihara Y; Shimanouchi T; Ino K; Uchimura K; Nishitsuji K
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33225-33234. PubMed ID: 33318190
[TBL] [Abstract][Full Text] [Related]
39. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
40. Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen.
Relini A; De Stefano S; Torrassa S; Cavalleri O; Rolandi R; Gliozzi A; Giorgetti S; Raimondi S; Marchese L; Verga L; Rossi A; Stoppini M; Bellotti V
J Biol Chem; 2008 Feb; 283(8):4912-20. PubMed ID: 18056266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
